Interferon-alpha therapy in patients with hepatitis C virus infection increases plasma phenylalanine and the phenylalanine to tyrosine ratio

Journal of Interferon and Cytokine Research

Volumn 32, Issue 5, 2012, Pages 216-220

  Zoller, Heinz ^a   Schloegl, Anna ^a   Schroecksnadel, Sebastian ^b   Vogel, Wolfgang ^a   Fuchs, Dietmar ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

NEOPTERIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; RIBAVIRIN; TYROSINE; VIRUS RNA;

ADULT; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MOOD CHANGE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; VIRUS LOAD;

ADULT; BIOSYNTHETIC PATHWAYS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEPACIVIRUS; HEPATITIS, CHRONIC; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOOD DISORDERS; PHENYLALANINE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; TYROSINE; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 84861392303     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2011.0093     Document Type: Article

References (48)

1. Amador-Cañizares Y, Dueñas-Carrera S. 2010. Early interferonbased treatment after detection of persistent hepatitis C virus infection: a critical decision. J Interferon Cytokine Res 30(11): 817-824.
2. Anderson DN, Wilkinson AM, Abou-Saleh MT, Blair JA. 1994. Recovery from depression after electroconvulsive therapy is accompanied by evidence of increased tetrahydrobiopterindependent hydroxylation. Acta Psychiatr Scand 90(1):10-13. (Pubitemid 24212166)
3. Bersano A, Aghemo A, Rumi MG, Ballabio E, Candelise L, Colombo M. 2008. Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. Eur J Intern Med 19(5):370-371. (Pubitemid 351790762)
4. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. 2002. Depression induced by treatment with interferonalpha in patients affected by hepatitis C virus. J Affect Disord 72(3):237-241. (Pubitemid 35351283)
5. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. 2000. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 69(2):228-232. (Pubitemid 30466029)
6. Braestrup C, Andersen H, Randrup A. 1975. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur J Pharmacol 34(1):181-187.
7. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, Miller AH. 2003. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry 54(9):906-914.
8. Capuron L, Schroecksnadel S, FÉart C, Aubert A, Higueret D, Barberger-Gateau P, LayÉ S, Fuchs D. 2011. Chronic lowgrade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 70(2):175-182.
9. Comai S, Cavalletto L, Chemello L, Bernardinello E, Ragazzi E, Costa CV, Bertazzo A. 2011. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C. Pharmacol Res 631(1):85-92.
10. Connor MJ, Pheasant AE, Blair JA. 1979. The identification of pacetamiobenzoate as a folate degradation product in rat urine. Biochem J 178(3):795-797.
11. Cozzi A, Zignego AL, Carpendo R, Biagiotti T, Aldinucci A, Monti M, Giannini C, Rosselli M, Laffi G, Moroni F. 2006. Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J Viral Hepat 13(6):402-408. (Pubitemid 44030262)
12. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. 2008. From inflammation to sickness and depression:when the immune system subjugates the brain. Nat Rev Neurosci 9(1):46-56. (Pubitemid 350295688)
13. Dunlop BW, Nemeroff CB. 2007. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64(3): 327-337. (Pubitemid 46376789)
14. Durastanti V, Lugaresi A, Bramanti P, Amato M, Bellantonio P, De Luca G, Picconi O, Fantozzi R, Locatelli L, Solda' A, Sessa E, Totaro R, Marino S, Zipoli V, Zorzon M, Millefiorini E. 2011. Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. Transl Med 2011;9:42.
15. Ferrando SJ, Goldman JD, Charness WE. 1997. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms. Gen Hosp Psychiatry 19(2):89-97. (Pubitemid 27146816)
16. Fitzpatrick PF. 1999. The tetrahydropterin-dependent amino acid hydroxylases. Annu Rev Biochem 68:355-381.
17. Fitzpatrick PF. 2003. Mechanism of aromatic amino acid hydroxylation. Biochemistry 42(48):14083-14091. (Pubitemid 37499404)
18. Fuchs D, Jaeger M, Widner B, Wirleitner B, Artner-Dworzak E, Leblhuber F. 2001. Is hyperhomocysteinemia due to oxidative depletion of folate rather than insufficient dietary intake. Clin Chem Lab Med 39(8):691-694. (Pubitemid 32894411)
19. Fuchs D, Norkrans G, Wejstal R, Reibnegger G, Weiss G, Weiland O, Schvarcz R, Fryden A, Wachter H. 1992. Changes of serum neopterin, b2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b. Eur J Med 1(4):196-200.
20. Fuchs JE, Huber RG, Wallnoefer HG, Von Grafenstein S, Spitzer GM, Fuchs D, Liedl KR. 2011. Side chain oxidation modulates local dynamics of phenylalanine hydroxylase. Pteridines 22(2):34-35.
21. Galvão-de Almeida A, Quarantini LC, Sampaio AS, Lyra AC, Parise CL, Paraná R, de Oliveira IR, Koenen KC, Miranda-Scippa A and Guindalini C. 2011. Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferonalpha-related depression in hepatitis C. Brain Behav Immun 25:1491-1497.
22. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD. 2002. A prospective study of the incidence and openlabel treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 79(9):942-947. (Pubitemid 35333048)
23. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H. 1984. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 160(1):310-316. (Pubitemid 14089799)
24. Hunchak J. 1997. SSRI combination treatment for depression. Can J Psychiatry 42(5):531-532.
25. Kapur S, Mann JJ. 1992. Role of the dopaminergic system in depression. Biol Psychiatry 32(1):1-17.
26. Konsman JP, Parnet P, Dantzer R. 2002. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 25(3):154-159. (Pubitemid 34164341)
27. Larrea E, Riezu-Boj JI, Gil-Guerrero L, Casares N, Aldabe R, Sarobe P, Civeira MP, Heeney JL, Rollier C, Verstrepen B, Wakita T, Borrás-Cuesta F, Lasarte JJ, Prieto J. 2007. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol 81(7):3662-3666. (Pubitemid 46456678)
28. Lin CC, Yin MC. 2009. Vitamins B depletion, lower iron status and decreased antioxidative defense in patients with chronic hepatitis C treated by pegylated interferon alfa and ribavirin. Clin Nutr 28(1):34-38.
29. Loftis JM, Morasco BJ, Menasco D, Fuchs D, Strater M, Hauser P. 2010. Serum serotonin levels are associated with antiviral therapy outcomes in patients with chronic hepatitis C. Open Infect Dis J 4:132-141.
30. Mayersbach P,Augustin R, SchennachH, SchönitzerD,Werner ER, Wachter H, Reibnegger G. 1994. Commercial enzyme-linked immunosorbent assay for neopterin detection in blood donations compared with RIA and HPLC. Clin. Chem 40:265-266.
31. Nathan CF, Murray HW, Wiebe ME, Rubin BY. 1983. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 158(3):670-689. (Pubitemid 13051337)
32. Neurauter G, Grahmann AV, Klieber M, Zeimet A, Ledochowski M, Sperner-Unterweger B, Fuchs D. 2008a. Serum phenylalanine concentrations in patients with ovarian carcinoma correlate with concentrations of immune activation markers and of isoprostane-8. Cancer Lett 272(1):141-147.
33. Neurauter G, Schröcksnadel K, Scholl-Bürgi S, Sperner-Unterweger B, Schubert C, Ledochowski M, Fuchs D. 2008b. Chronic immune stimulation correlates with reduced phenylalanine turn-over. Curr Drug Metabol 9(7):622-627.
34. Ollenschläger G, Jansen S, Schindler J, Rasokat H, Schrappe-Bächer M, Roth E. 1988. Plasma amino acid pattern of patients with HIV infection. Clin Chem 34(9):1787-1789.
35. Ploder M, Neurauter G, Spittler A, Schroecksnadel K, Roth E, Fuchs D. 2008. Serum phenylalanine in patients post trauma and with sepsis correlate to neopterin concentrations. Amino Acids 35(2):303-307.
36. Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. 2005. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 19(1):23-27. (Pubitemid 39592806)
37. Ramos EL. 2010. Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res 30(8):591-595.
38. Rath T, Roth E, Keidl R, Meissl G. 1987. Phenylalanine: total amino acid ratio in 45 burn patients. Scand J Plast Reconstr Surg Hand Surg 12(3):297-300. (Pubitemid 18005257)
39. Rosenblatt D, Scriver CR. 1968. Heterogeneity in genetic control of phenylalanine metabolism in man. Nature 218(5142): 677-678.
40. Schroeder BO, Wu Z, Nuding S, Groscurth S, Marcinowski M, Beisner J, Buchner J, Schaller M, Stange EF, Wehkamp J. 2010. Reduction of disulphide bonds unmasks potent antimicrobial activity of human b-defensin 1. Nature 469(7330):419-423.
41. Shintaku H. 2002. Disorders of tetrahydrobiopterin metabolism and their treatment. Curr Drug Metab 3(2):123-131. (Pubitemid 34326526)
42. Stein DJ. 2008. Depression, anhedonia, and psychomotor symptoms: the role of dopaminergic neurocircuitry. CNS Spectr 13(7):561-565.
43. Widner B, Laich A, Sperner-Unterweger B, Ledochowski M, Fuchs D. 2002. Neopterin production tryptophan degradation and mental depression: what is the link? Brain Behav Immun 16(5):590-595. (Pubitemid 35333739)
44. Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, Wachter H. 1989. Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-gamma. Biochem J 262(3):861-866. (Pubitemid 19225160)
45. Wirleitner B, Reider D, Ebner S, Böck G, Widner B, Jaeger M, Schennach H, Romani N, Fuchs D. 2002. Monocyte-derived dendritic cells release neopterin. J Leukoc Biol 72(6):1148-1153. (Pubitemid 36008885)
46. Zangerle R, Kurz K, Neurauter G, Kitchen M, Sarcletti M, Fuchs D. 2010. Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective antiretroviral therapy. Brain Behav Immun 24(3):403-408.
47. Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, Sarrazin C, Hueppe D, Zehnter E, Manns MP. 2009. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 16(2):75-90.
48. Zignego AL, Cozzi A, Carpenedo R, Giannini C, Rosselli M, Biagioli T, Aldinucci A, Laffi G, Moroni F. 2007. HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. Dig Liver Dis 39(Suppl 1.):S107-S111. (Pubitemid 47528200)